CAG
BCRX icon

Csenge Advisory Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Csenge Advisory Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Hold
25,000
– – 0.01% 669
2026
Q1 		$238K Hold
25,000
– – 0.01% 652
2025
Q4 		$195K Hold
25,000
– – 0.01% 690
2025
Q3 		$190K Buy
+25,000
New +$208K 0.01% 663

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Csenge Advisory Group's BCRX Position: Q2 2026 in Review

Csenge Advisory Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 25,000 shares worth $250K. The position accounts for 0.01% of the portfolio, ranked #669.

Csenge Advisory Group first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Csenge Advisory Group held 25,000 shares of BioCryst Pharmaceuticals worth $250K as of Q2 2026.
  • Csenge Advisory Group left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.01% of Csenge Advisory Group's portfolio in Q2 2026, its #669 holding.
  • Csenge Advisory Group first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.